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Clear evidence supports the value of oral anticoagulation
(OAC) with vitamin K antagonists in preventing stroke and
thromboembolism in patients with atrial ﬁbrillation (AF)
who have well-established risk factors. For this indication,
vitamin K antagonists have been shown to be superior to
single or dual antiplatelet agents in reducing thromboem-
bolic complications (1). Yet, up to 30% of patients with AF
also have indications for antiplatelet therapy because of
coronary artery disease (2). Dual antiplatelet therapy with
aspirin and a P2Y12 receptor inhibitor (e.g., clopidogrel) is
usually recommended after stent implantation or acuteSee page 981coronary syndrome (3). Thus, patients with both AF and
coronary events typically receive combination OAC and
antiplatelet therapy. There has been concern that with-
holding antiplatelet therapy in these patients could expose
them to higher rates of stent thrombosis and myocardial
infarction (MI), and P2Y12 inhibitors seem to be particularly
important in this regard. Yet, the combination of OAC with
antiplatelet drugs clearly increases the risk of major
hemorrhages and fatal bleeding in both AF and coronary
populations (4–6). European guidelines from 2010 suggest
triple therapy after stent implantation, with the duration
depending on the type of stent implanted, the presence of an
acute coronary syndrome, and the bleeding risk of the
patient. (7) An earlier guideline document from the
American College of Cardiology, American Heart Associ-
ation, and European Society of Cardiology de-emphasizes
the use of aspirin and favors OAC þ clopidogrel after
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more risk than beneﬁt” (8). For patients with both AF and
coronary disease, there is a paucity of information to guide
rational decisions and very little evidence to support inten-
sive anticoagulation with triple therapy.
In this issue of the Journal, Lamberts et al. (9) used national
databanks and registries in Denmark to explore the safety and
efﬁcacy of different anticoagulation regimens in patients with
AF who also had MI and/or percutaneous coronary interven-
tion (PCI). Because patients in Denmark have unique identi-
ﬁers, the investigators could link national databases of hospital
stays, procedural treatments, drug prescriptions, and causes of
death. This analysis has the advantage of studying outcomes in
a large “real world” population, not one highly selected by
rigorous inclusion criteria of a randomized trial. It also illus-
trates the power of nationwide registries to explore clinically
important questions that might prove difﬁcult to approach in
randomized trials. As with any retrospective registry, some
important data might not be available. For example, this study
does not inform us how many PCI patients had drug-eluting
stents. Also, registry studies that use hospital diagnosis codes
depend heavily on the accuracy of the coding. Fortunately, the
codes employed in this study have been previously validated
with relatively high speciﬁcities and predictive values.
With this approach, 12,165 AF patients were identiﬁed
who were hospitalized for MI and/or PCI. Anticoagulation
regimens were monotherapy in 38% (aspirin, clopidogrel, or
OAC), dual therapy in 47% (dual antiplatelets or OAC þ 1
antiplatelet), and triple therapy in 15%. Outcomes assessed
after 1 year included MI, ischemic stroke, mortality, and
bleeding, as judged from hospital stay and death records. In
this analysis, OAC þ clopidogrel emerged as the favored
overall strategy. Compared with triple therapy, this dual
combination showed no excess of MI or coronary death,
and there was no difference in ischemic stroke or overall
mortality. In terms of bleeding, OAC þ clopidogrel showed
a nonsigniﬁcant beneﬁt compared with triple therapy. Other
regimens (OAC þ aspirin; dual antiplatelet therapy without
OAC) were associated with less bleeding but at the cost of
higher all-cause mortality rates. Not surprisingly, there were
also more strokes among those treated with dual antiplatelets
compared with any regimen that used an OAC. Those who
hadPCIwithoutMI had a lower coronary event rate, but there
was still a beneﬁt for OAC þ clopidogrel compared with the
other regimens in these lower-risk patients. Other interesting
ﬁndings were high subsequent mortality, MI, and stroke
among those hospitalized for bleeding compared with those
without. The higher rates of thrombotic events among those
with nonfatal bleeding suggest that bleeding is dangerous not
only because of the hemorrhage itself but also because it forces
discontinuation of needed anticoagulation.
A limitation of this study design is the possibility that
treatment decisions were confounded by many clinical
features that cannot be captured from the national databases.
The authors acknowledge this important limitation and
report that baseline characteristicsdsuch as CHADS2 and
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choice of anticoagulation prescriptions. But it should be
acknowledged that even this analysis does not control for
other comorbidities that might lead physicians to choose
a particular anticoagulation regimen (clopidogrel alone vs.
the combination of aspirin þ clopidogrel) after a new cardiac
event. Finally, the number of patients who were initially
prescribed the “optimal” regimen of OAC þ clopidogrel was
relatively small (548 of 12,615 subjects).
The question of dual versus triple anticoagulation has
recently been addressed in a prospective, randomized trial
(WOEST [What is the Optimal AntiplatElet and antico-
agulant therapy in patients with oral anticoagulation and
coronary StenTing] trial) (10). This trial tested OAC þ
clopidogrel versus triple therapy in patients undergoing
coronary stenting who also needed OAC (for AF in 69%).
After 1 year of follow-up, OAC þ clopidogrel was associ-
ated with signiﬁcantly less overall bleeding, and there was no
increase in stent thrombosis, although this relatively small
study of 573 patients was underpowered to exclude excess
stent thrombosis. In composite, these 2 studies suggest dual
anticoagulation with OAC þ clopidogrel as a safer and
perhaps equally effective strategy compared with triple
therapy.
But a myriad of questions remain unanswered. Could
there be even higher-risk patients in whom coronary
protection with triple therapy outweighs the bleeding risks?
For example, patients with recurrent coronary events within
1 year would be considered at elevated risk, but patients
with MI in the previous year were excluded from the
Danish study. Also, this study does not address the time
course of triple or even dual therapy after MI or PCI.
Current guidelines suggest that monotherapy with warfarin
might be sufﬁcient 1 year after stenting in lower-risk
patients (7,8), an issue that is not addressed in the present
study. Even more perplexing is how to treat patients with
resistance to clopidogrel. These patients might be candi-
dates for other P2Y12 inhibitors, but sparse data are available
on the combination of OAC with newer P2Y12 receptor
inhibitors (prasugrel, ticagrelor), which are shown to reduce
coronary endpoints but at the expense of more bleeding
(11,12). Preliminary evidence suggests more bleeding occurs
in triple therapy patients receiving prasugrel compared with
clopidogrel (13). Finally, these results cannot necessarily be
extrapolated to the newer direct thrombin and factor Xa
inhibitors, but it is probable that combining these new
agents with dual antiplatelets would cause more bleeding
than beneﬁt (14).
The implication here is that physicians should have
conﬁdence to curtail triple therapy when OAC is needed for
AF. One method to minimize the need for combination
therapy is to use bare-metal stents whenever possible in AF
patients. New stent designs are likely to reduce the need for
triple therapy in the future. Ultimately, the clinician must
exercise judgment and integrate bleeding and thromboticrisks in prescribing anticoagulation regimens in such
situations.
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